Momelotinib｜Anemic｜HongKong DengYue Medicine

Momelotinib  Application Scope

Momelotinib is primarily used for the treatment of myelofibrosis (MF), including primary myelofibrosis (PMF) and secondary myelofibrosis (SMF) (post-polycythemia vera and post-essential thrombocythemia).

It is particularly beneficial for patients with moderate to severe anemia, as it improves symptoms, reduces spleen size, and decreases transfusion dependency.

Characteristics

• Ingredients: Momelotinib (CYT387, LM-1149, CYT11387)​

• Properties: ATP-competitive inhibitor of JAK1, JAK2, and ACVR1/ALK2; induces apoptosis and autophagy.​

• Specification: 10mg, 50mg, 1g (vials or tablets, depending on formulation).​

• Packaging Specification: Sealed, light-protected containers.​

• Storage: Store in a cool, dry place, protected from light and moisture.​

• Expiry Date: Typically 2-3 years from manufacturing date (check packaging for specifics).​

• Executive Standard: FDA-approved (US), PBS-listed (Australia).​

• Approval Number: Varies by region (e.g., FDA NDA approval for Ojjaara® in 2023)​

• Date of Revision: Latest updates as of April 2025 (PBS Australia).​

• Manufacturer: Originally developed by Gilead, acquired by Sierra Oncology, now marketed by GSK (Ojjaara®).​

Guidelines For The Use Of Momelotinib

Dosage and Administration

• Standard dose: Typically 200 mg once daily (oral administration).
• Adjustments may be needed for thrombocytopenia or severe adverse reactions.

Adverse Reactions

• Common: Thrombocytopenia, anemia, fatigue, dizziness, diarrhea, nausea, infections.
• Severe (rare): Peripheral neuropathy, bleeding complications.

Contraindications

• Hypersensitivity to momelotinib or its components.
• Severe hepatic impairment (use with caution).

Precautions

• Monitor blood counts (risk of anemia, thrombocytopenia).
• Assess for peripheral neuropathy.
• Avoid in pregnancy (potential fetal harm).

Interactions

• Strong CYP3A4 inhibitors/inducers may alter momelotinib levels.
• Anticoagulants/antiplatelets (increased bleeding risk).

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.